NZ627781A - Neuroactive steroid formulations and methods of treating cns disorders - Google Patents
Neuroactive steroid formulations and methods of treating cns disordersInfo
- Publication number
- NZ627781A NZ627781A NZ627781A NZ62778113A NZ627781A NZ 627781 A NZ627781 A NZ 627781A NZ 627781 A NZ627781 A NZ 627781A NZ 62778113 A NZ62778113 A NZ 62778113A NZ 627781 A NZ627781 A NZ 627781A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- cns disorders
- neuroactive steroid
- treating cns
- steroid formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261589740P | 2012-01-23 | 2012-01-23 | |
| PCT/US2013/022772 WO2013112605A2 (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ627781A true NZ627781A (en) | 2016-10-28 |
Family
ID=48874058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ627781A NZ627781A (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
| NZ773177A NZ773177A (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ773177A NZ773177A (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US20150018327A1 (enExample) |
| EP (3) | EP2806877B2 (enExample) |
| JP (5) | JP2015513316A (enExample) |
| CN (2) | CN112472814A (enExample) |
| AU (3) | AU2013212287B2 (enExample) |
| BR (1) | BR112014018110B1 (enExample) |
| CA (1) | CA2862076C (enExample) |
| CY (1) | CY1122527T1 (enExample) |
| DK (1) | DK2806877T3 (enExample) |
| ES (1) | ES2758446T3 (enExample) |
| HR (1) | HRP20192348T1 (enExample) |
| HU (1) | HUE046800T2 (enExample) |
| IL (4) | IL298436B2 (enExample) |
| LT (1) | LT2806877T (enExample) |
| MX (3) | MX2014008895A (enExample) |
| NZ (2) | NZ627781A (enExample) |
| PL (1) | PL2806877T3 (enExample) |
| PT (1) | PT2806877T (enExample) |
| RS (1) | RS59734B1 (enExample) |
| RU (2) | RU2681835C2 (enExample) |
| SG (2) | SG11201503882SA (enExample) |
| SI (1) | SI2806877T1 (enExample) |
| SM (1) | SMT202000008T1 (enExample) |
| WO (1) | WO2013112605A2 (enExample) |
| ZA (1) | ZA201405401B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| BR112015003747A2 (pt) * | 2012-08-21 | 2017-07-04 | Sage Therapeutics Inc | métodos de tratamento de epilepsia ou estado de mal epiléptico |
| WO2014071449A1 (en) * | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| SG10201802389SA (en) | 2013-04-17 | 2018-04-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| AR102306A1 (es) | 2014-10-16 | 2017-02-15 | Sage Therapeutics Inc | Esteroides neuroactivos útiles en el tratamiento de enfermedades del snc |
| EP3224269B1 (en) | 2014-11-27 | 2020-02-26 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US20180311258A1 (en) | 2015-04-10 | 2018-11-01 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| KR20180052611A (ko) | 2015-08-18 | 2018-05-18 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 영상화 및 치료 용도를 위한 니트록사이드 함유 아밀로이드 결합 제제 |
| EP3362042A1 (en) * | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| CN113616661A (zh) | 2016-03-08 | 2021-11-09 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
| US10858338B2 (en) | 2016-03-15 | 2020-12-08 | The Regents Of The University Of California | Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) |
| EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| ES2965214T3 (es) | 2016-07-11 | 2024-04-11 | Sage Therapeutics Inc | Esteroides neuroactivos sustituidos en C17, C20 y C21 y sus procedimientos de utilización |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| US20180050005A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| US20180050107A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108148106A (zh) | 2016-12-05 | 2018-06-12 | 江苏恩华络康药物研发有限公司 | 一类水溶性别孕烯醇酮衍生物及其用途 |
| US20210228596A1 (en) | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| CN111565724A (zh) * | 2017-11-10 | 2020-08-21 | 马瑞纳斯制药公司 | 加奈索酮用于治疗遗传性癫痫病 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| WO2020011789A1 (en) | 2018-07-09 | 2020-01-16 | Asarina Pharma Ab | Injectable suspensions |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| US20220202832A1 (en) * | 2019-04-05 | 2022-06-30 | The Regents Of The University Of California | Allopregnanolone compositions and uses thereof |
| WO2020231837A1 (en) | 2019-05-10 | 2020-11-19 | Brii Biosciences, Inc. | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof |
| CN114728012A (zh) | 2019-08-05 | 2022-07-08 | 马瑞纳斯制药公司 | 用于治疗癫痫持续状态的加奈索酮 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| AU2020395254A1 (en) | 2019-12-06 | 2022-06-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| BR112022019085A2 (pt) | 2020-03-25 | 2023-01-31 | Sage Therapeutics Inc | Uso de agentes para tratamento de condições respiratórias |
| CN116917134A (zh) * | 2020-12-02 | 2023-10-20 | 约翰霍普金斯大学 | 用于神经调节剂的包封和持续释放的聚合物纳米颗粒组合物 |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US20240368212A1 (en) * | 2021-08-26 | 2024-11-07 | Brandeis University | Selective isonitrile inhibitors of cytochrome p450 subtypes |
| EP4403565A4 (en) | 2021-09-14 | 2025-02-19 | Nanjing Minova Pharmaceutical Co., Ltd. | WATER-SOLUBLE ALLOPREGNANOLONE DERIVATIVE AND MANUFACTURING PROCESS AND USE THEREOF |
| WO2023240100A1 (en) * | 2022-06-07 | 2023-12-14 | Clarkson Clay Carew | A method to encapsulate non-polar compounds to achieve extended thermal stability and attenuate/prevent thermal and redox isomerization |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2443266A (en) * | 1944-09-02 | 1948-06-15 | Bendix Aviat Corp | Commutator brush holder |
| US3117142A (en) | 1961-03-01 | 1964-01-07 | Roussel Uclaf | Novel preparation of estradiol and estrone |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| US5847009A (en) | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
| SE8600632D0 (sv) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | Novel pharmaceutical composition |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| US5411737A (en) | 1991-10-15 | 1995-05-02 | Merck & Co., Inc. | Slow release syneresing polymeric drug delivery device |
| EP0701444B1 (en) | 1993-05-24 | 2010-04-07 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| DK0752860T3 (da) | 1994-02-14 | 2000-11-13 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| CZ292881B6 (cs) | 1994-11-23 | 2003-12-17 | Euro-Celtique S.A. | Androstanová a pregnanová řada pro allosterickou modulaci GABA receptoru |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| AU725214B2 (en) | 1995-06-06 | 2000-10-05 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6316613B1 (en) | 1997-07-25 | 2001-11-13 | Beckman Coulter, Inc. | Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis |
| US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| AU756001B2 (en) | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
| US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| DE60001623T2 (de) | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| US6442887B2 (en) | 2000-02-25 | 2002-09-03 | Robert L. Sanquist | Live bait keeper |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| WO2002064804A2 (en) | 2001-02-13 | 2002-08-22 | University Of Florida | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US20030032638A1 (en) | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| AU2002310085B2 (en) | 2001-05-24 | 2008-09-04 | Alexza Pharmaceuticals, Inc. | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| JP2003063965A (ja) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| AU2003252827B2 (en) | 2002-01-14 | 2008-01-10 | Ansell Healthcare Products Llc | Magnetically detectable latex articles |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| EP2298316A1 (en) | 2002-08-28 | 2011-03-23 | Harbor BioSciences, Inc. | Therapeutic treatment methods |
| US9339508B2 (en) | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
| WO2005000869A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| US7816074B2 (en) | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| JP2007515425A (ja) * | 2003-12-22 | 2007-06-14 | シェーリング コーポレイション | 医薬組成物 |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ATE497787T1 (de) | 2004-03-12 | 2011-02-15 | Cipla Ltd | Sterilisationsprozess für steroide |
| US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| ITMI20041763A1 (it) | 2004-09-16 | 2004-12-16 | Altergon Sa | Nuove formulazioni iniettabili contenenti progesterone |
| US20060063707A1 (en) | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| EP2471536A1 (en) | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
| ATE499109T1 (de) | 2004-12-07 | 2011-03-15 | Proteolix Inc | Zusammensetzung zur proteasomhemmung |
| EP1853234A2 (en) | 2005-02-15 | 2007-11-14 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
| DK1868614T3 (da) | 2005-03-24 | 2012-11-12 | Univ Emory | Dosisregime til behandling af en traumatisk hjerneskade med progesteron |
| WO2006110642A2 (en) | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| KR100784860B1 (ko) | 2005-10-31 | 2007-12-14 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그 제조 방법 |
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
| ES2397746T3 (es) | 2007-04-11 | 2013-03-11 | Biomarin Pharmaceutical Inc. | Métodos de administración de tetrahidrobiopterina, composiciones asociadas y métodos de medición |
| US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| WO2008154579A1 (en) * | 2007-06-11 | 2008-12-18 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| JP5663303B2 (ja) | 2007-06-15 | 2015-02-04 | リサーチ トライアングル インスティテュート | Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| EP2175886A1 (en) | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| EP2254577A1 (en) | 2007-12-26 | 2010-12-01 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ |
| EP2224927B1 (en) | 2008-01-03 | 2014-08-20 | BioMarin Pharmaceutical Inc. | Pterin analog for treating bh4 responsive condition |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
| DE102008015366A1 (de) | 2008-03-20 | 2009-09-24 | Merck Patent Gmbh | Lyophilisierte Nanoemulsion |
| WO2010063030A2 (en) | 2008-11-30 | 2010-06-03 | Feigelson, Daniel | Dermal application of vasoconstrictors |
| CZ301216B6 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| DK2356109T3 (en) | 2008-10-10 | 2017-03-13 | Vm Discovery Inc | COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES |
| US20110306579A1 (en) * | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| US20120142645A1 (en) | 2009-03-17 | 2012-06-07 | Marx Christine E | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| GB2491491B (en) * | 2010-01-21 | 2014-07-30 | Drawbridge Pharmaceuticals Pty Ltd | Anaesthetic formulation |
| BR112013010342A8 (pt) | 2010-11-03 | 2018-04-03 | Sanofi Aventis Deutschland | módulo contendo medicamento e cânula da agulha |
| US20130309306A1 (en) | 2010-12-01 | 2013-11-21 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| WO2012116290A2 (en) | 2011-02-25 | 2012-08-30 | Washington University | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| FR2973031B1 (fr) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| DK2753632T3 (da) | 2011-09-08 | 2023-07-10 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelse heraf |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| EP3572417B1 (en) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| KR101686719B1 (ko) | 2011-11-29 | 2016-12-14 | 가부시키가이샤 아미노 압 가가쿠 | 진경제 및/또는 위장관운동 촉진제 용도의 비세닌 2 및 이의 유사체 |
| ES2784629T3 (es) | 2011-11-29 | 2020-09-29 | Jurox Pty Ltd | Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona |
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| BR112015003747A2 (pt) | 2012-08-21 | 2017-07-04 | Sage Therapeutics Inc | métodos de tratamento de epilepsia ou estado de mal epiléptico |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| KR101993899B1 (ko) | 2012-12-18 | 2019-09-24 | 워싱톤 유니버시티 | 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법 |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| SG10201802389SA (en) | 2013-04-17 | 2018-04-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| ES2998982T3 (en) | 2013-04-17 | 2025-02-24 | Sage Therapeutics Inc | 19-nor neuroactive steroids for inducing sedation |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN115487313A (zh) | 2015-02-06 | 2022-12-20 | 马瑞纳斯制药公司 | 静脉内加奈索酮制剂及其用途 |
| GB2541015A (en) | 2015-08-06 | 2017-02-08 | Ge Oil & Gas Uk Ltd | Subsea flying lead |
| EP3362069A4 (en) | 2015-10-14 | 2019-10-02 | The Regents of The University of California | INCREASING BETA CELL REPLICATION AND / OR SURVIVAL |
| CN113616661A (zh) | 2016-03-08 | 2021-11-09 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
| US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| EP3509585B1 (en) | 2016-09-07 | 2023-11-01 | Glia, LLC | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018169798A1 (en) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
| EP3612186A1 (en) | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| US11752115B2 (en) | 2017-06-21 | 2023-09-12 | The Board Of Trustees Of The University Of Illinois | PPAR-alpha agonist treatment of neuropsychiatric disorders |
| AU2018290348B2 (en) | 2017-06-23 | 2024-04-04 | Ayikoe-Guy MENSAH-NYAGAN | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| CA3104810A1 (en) | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | Enhancing gaba's ability to modulate immune responses |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| CA3075872A1 (en) | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN111565724A (zh) | 2017-11-10 | 2020-08-21 | 马瑞纳斯制药公司 | 加奈索酮用于治疗遗传性癫痫病 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| JP2021506904A (ja) | 2017-12-22 | 2021-02-22 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置のための組成物および方法 |
| JP7382326B2 (ja) | 2017-12-22 | 2023-11-16 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置のための組成物および方法 |
| US11718642B2 (en) | 2018-01-12 | 2023-08-08 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| EP3788055A4 (en) | 2018-05-04 | 2022-03-30 | Acerus Pharmaceuticals Corporation | Neurosteroid derivatives and uses thereof |
| MX2020013557A (es) | 2018-06-12 | 2021-05-27 | Sage Therapeutics Inc | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. |
| DK3864022T3 (da) | 2018-10-12 | 2023-12-18 | Sage Therapeutics Inc | Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser |
| CA3116892A1 (en) | 2018-10-19 | 2020-04-23 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| EP3902818A1 (en) | 2018-12-05 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| TWI848034B (zh) | 2018-12-21 | 2024-07-11 | 美商賽吉醫療公司 | 神經活性類固醇及其組合物 |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| US11643434B2 (en) | 2019-05-31 | 2023-05-09 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| IL293510A (en) | 2019-12-05 | 2022-08-01 | Sage Therapeutics Inc | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| TW202143976A (zh) | 2020-03-18 | 2021-12-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| BR112022019085A2 (pt) | 2020-03-25 | 2023-01-31 | Sage Therapeutics Inc | Uso de agentes para tratamento de condições respiratórias |
| AR123018A1 (es) | 2020-07-20 | 2022-10-26 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este |
-
2013
- 2013-01-23 EP EP13740743.3A patent/EP2806877B2/en active Active
- 2013-01-23 PT PT137407433T patent/PT2806877T/pt unknown
- 2013-01-23 RS RS20191698A patent/RS59734B1/sr unknown
- 2013-01-23 US US14/374,080 patent/US20150018327A1/en not_active Abandoned
- 2013-01-23 WO PCT/US2013/022772 patent/WO2013112605A2/en not_active Ceased
- 2013-01-23 CN CN202011230446.5A patent/CN112472814A/zh active Pending
- 2013-01-23 HR HRP20192348TT patent/HRP20192348T1/hr unknown
- 2013-01-23 CN CN201380015855.5A patent/CN104736158A/zh active Pending
- 2013-01-23 EP EP23192903.5A patent/EP4295908A3/en not_active Withdrawn
- 2013-01-23 MX MX2014008895A patent/MX2014008895A/es active IP Right Grant
- 2013-01-23 SG SG11201503882SA patent/SG11201503882SA/en unknown
- 2013-01-23 DK DK13740743T patent/DK2806877T3/da active
- 2013-01-23 RU RU2014134316A patent/RU2681835C2/ru active
- 2013-01-23 NZ NZ627781A patent/NZ627781A/en unknown
- 2013-01-23 AU AU2013212287A patent/AU2013212287B2/en active Active
- 2013-01-23 RU RU2019104004A patent/RU2019104004A/ru unknown
- 2013-01-23 ES ES13740743T patent/ES2758446T3/es active Active
- 2013-01-23 HU HUE13740743A patent/HUE046800T2/hu unknown
- 2013-01-23 BR BR112014018110-1A patent/BR112014018110B1/pt active IP Right Grant
- 2013-01-23 JP JP2014553534A patent/JP2015513316A/ja not_active Withdrawn
- 2013-01-23 SG SG10201606063RA patent/SG10201606063RA/en unknown
- 2013-01-23 CA CA2862076A patent/CA2862076C/en active Active
- 2013-01-23 LT LT13740743T patent/LT2806877T/lt unknown
- 2013-01-23 PL PL13740743T patent/PL2806877T3/pl unknown
- 2013-01-23 IL IL298436A patent/IL298436B2/en unknown
- 2013-01-23 NZ NZ773177A patent/NZ773177A/en unknown
- 2013-01-23 IL IL286348A patent/IL286348B2/en unknown
- 2013-01-23 EP EP19195977.4A patent/EP3650027A1/en not_active Withdrawn
- 2013-01-23 SI SI201331627T patent/SI2806877T1/sl unknown
- 2013-01-23 SM SM20200008T patent/SMT202000008T1/it unknown
-
2014
- 2014-07-22 ZA ZA2014/05401A patent/ZA201405401B/en unknown
- 2014-07-22 IL IL233744A patent/IL233744B/en active IP Right Grant
- 2014-07-23 MX MX2022010976A patent/MX2022010976A/es unknown
- 2014-07-23 MX MX2019009739A patent/MX2019009739A/es unknown
-
2017
- 2017-07-13 US US15/649,583 patent/US10322139B2/en active Active
- 2017-12-11 JP JP2017236676A patent/JP2018076341A/ja active Pending
-
2018
- 2018-02-22 AU AU2018201307A patent/AU2018201307B2/en active Active
-
2019
- 2019-04-26 US US16/396,065 patent/US11426417B2/en active Active
- 2019-12-12 CY CY20191101309T patent/CY1122527T1/el unknown
-
2020
- 2020-05-11 JP JP2020082943A patent/JP2020128409A/ja active Pending
- 2020-07-30 IL IL276403A patent/IL276403B/en unknown
- 2020-08-13 AU AU2020217402A patent/AU2020217402B2/en active Active
-
2022
- 2022-04-26 JP JP2022072014A patent/JP7343651B2/ja active Active
- 2022-07-20 US US17/869,145 patent/US20230149424A1/en not_active Abandoned
-
2023
- 2023-08-31 JP JP2023140708A patent/JP2023162368A/ja active Pending
-
2024
- 2024-07-11 US US18/769,514 patent/US20250186459A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ627781A (en) | Neuroactive steroid formulations and methods of treating cns disorders | |
| MX362543B (es) | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX354210B (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501404A1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| MX2015014438A (es) | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EP2968881A4 (en) | APPARATUS, SYSTEMS AND METHODS FOR BRAIN MEDICATION ADMINISTRATION FOR TREATING NEUROLOGICAL CONDITIONS | |
| IN2015DN03219A (enExample) | ||
| PH12015501596B1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015500062A1 (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| EP2857011A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF COGNITIVE, PSYCHIC OR BEHAVIORAL DISORDERS | |
| LT2774991T (lt) | Vaisto įvedimo sistema, skirta naudoti neurologinių sutrikimų gydymui arba diagnostikai | |
| HUE038580T2 (hu) | Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| PH12014501573A1 (en) | Topical pharmaceutical compositions comprising bexarotene and a corticosteroids | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| UA59968U (ru) | Комплексная система для арттерапии и ароматерапии | |
| Ito | Investigation of a new treatment outcome index for tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 JAN 2020 BY CULLENS PTY LTD Effective date: 20170515 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2021 BY COMPUTER PACKAGES INC Effective date: 20200131 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2022 BY CPA GLOBAL Effective date: 20201224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2023 BY CPA GLOBAL Effective date: 20211210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2024 BY CPA GLOBAL Effective date: 20221209 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2025 BY CPA GLOBAL Effective date: 20231207 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241227 |